S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

ContraFect Stock Price, News & Analysis (NASDAQ:CFRX)

$0.05
-0.02 (-28.57%)
(As of 12/5/2023)
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.57
52-Week Range
$0.04
$13.02
Volume
910,216 shs
Average Volume
1.39 million shs
Market Capitalization
$535,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

ContraFect MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5,900.0% Upside
$3.00 Price Target
Short Interest
Healthy
1.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.44) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars


CFRX stock logo

About ContraFect Stock (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

CFRX Stock Price History

CFRX Stock News Headlines

ContraFect (NASDAQ:CFRX) Coverage Initiated at StockNews.com
ContraFect Corp CFRX
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
ContraFect: Q3 Earnings Snapshot
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
CFRX: IND Application for CF-370 Submitted to FDA…
CFRX: CF-370 IND to be Filed in 3Q23…
ContraFect (CFRX) Receives a Buy from Maxim Group
ContraFect: Q2 Earnings Snapshot
ContraFect Corp
8-K: CONTRAFECT Corp
See More Headlines
Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+5,900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-65,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($19.92) per share

Miscellaneous

Free Float
10,639,000
Market Cap
$535,000.00
Optionable
Not Optionable
Beta
0.29
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Roger James Pomerantz FACP (Age 66)
    M.D., Chairman, CEO & President
    Comp: $970.72k
  • Mr. Michael Messinger CPA (Age 48)
    Chief Financial Officer
    Comp: $543.14k
  • Ms. Natalie Bogdanos J.D. (Age 54)
    General Counsel, Corporate Secretary & Data Protection Officer
    Comp: $531.2k
  • Mr. Matthew Salamone P.H.R.
    SPHR, Vice President of Human Resources
  • Dr. Gary Woodnutt (Age 66)
    Senior Vice President of Translational Sciences & Preclinical Development
  • Dr. William Garrett Nichols M.D. (Age 54)
    M.S., Interim Chief Medical Officer














CFRX Stock Analysis - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings
or view top-rated stocks.

What is ContraFect's stock price target for 2024?

1 brokerages have issued 1 year price targets for ContraFect's shares. Their CFRX share price targets range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 5,900.0% from the stock's current price.
View analysts price targets for CFRX
or view top-rated stocks among Wall Street analysts.

How have CFRX shares performed in 2023?

ContraFect's stock was trading at $7.68 at the start of the year. Since then, CFRX shares have decreased by 99.3% and is now trading at $0.05.
View the best growth stocks for 2023 here
.

Are investors shorting ContraFect?

ContraFect saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 59,600 shares, a decline of 48.6% from the October 15th total of 116,000 shares. Based on an average daily volume of 217,000 shares, the short-interest ratio is presently 0.3 days. Currently, 1.1% of the shares of the company are short sold.
View ContraFect's Short Interest
.

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) announced its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.16.

When did ContraFect's stock split?

ContraFect shares reverse split on the morning of Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.44%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of ContraFect?

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CFRX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -